Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : India hopes U.S. will soon ease ban on vaccine material exports - sources

04/20/2021 | 01:23am EDT
A man reacts as he receives a dose of the COVISHIELD coronavirus disease (COVID-19) vaccine, in Ahmedabad

NEW DELHI (Reuters) - India is hopeful the United States will soon lift a ban on the export of vaccine raw materials that threatens to slow India's inoculation drive, two Indian government sources told Reuters on Monday, after the foreign ministers of the two nations spoke.

One official said the Biden administration had told India that its request for a lifting of the ban was being considered and would be acted upon "at the earliest".

Indian Foreign Minister Subrahmanyam Jaishankar tweeted that he and U.S. Secretary of State Antony Blinken had discussed, among other things, "issues pertaining to our health cooperation".

The Indian foreign ministry declined to elaborate. The U.S. State Department confirmed the two diplomats discussed COVID-19, but did not give details.

India is currently facing the world's worst surge in coronavirus infections, which has led to a clamour for vaccines. The country with the world's biggest vaccine-making capacity has also stopped major exports to meet domestic demand.

Jaishankar confirmed on Monday that the government was trying to address the raw materials matter but that it was important for India to meet its export commitments too.

"I am pushing other countries, particularly some big countries, saying 'Look, please keep the raw materials flowing for the vaccines to be made in India'," he said, without naming any country.

"Can I ... go around the world and tell people 'Guys keep your supply chain flowing towards me ... but I am not going to give you the vaccine?'"

Washington has invoked the Defense Production Act to preserve vaccine raw materials for its own companies, but the Serum Institute of India (SII), the world's biggest vaccine maker, has said this went against the global goal of sharing vaccines equitably.

Asked about the restrictions on exports, White House press secretary Jen Psaki said inequities in access to vaccines were "completely unacceptable", but declined to detail additional U.S. action to address that.

SII is licensed to make the AstraZeneca shot as well another developed by U.S. company Novavax.

(Additional reporting by Sanjeev Miglani, Euan Rocha and Simon Lewis; Writing by Krishna N. Das; Editing by William Maclean and Stephen Coates)

By Rupam Jain and Neha Arora

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.15% 7864 Delayed Quote.7.37%
NOVAVAX, INC. 8.83% 131.69 Delayed Quote.18.10%
All news about ASTRAZENECA PLC
04:03aASTRAZENECA  : Family doctors say they can answer vaccine questions, after Trude..
01:37aASTRAZENECA  : India hopes COVID-19 cases stabilising even as daily deaths stay ..
05/14Taiwan tightens curbs after surge in domestic COVID-19 cases
05/14ASTRAZENECA  : Experts call on Canada to use COVAX doses of AstraZeneca or give ..
05/14ASTRAZENECA  : You Want It When?! EU Sues AstraZeneca Over Vaccine Delivery Dela..
05/14ASTRAZENECA  : Angola Calls for Equity in Vaccine Distribution
05/14ASTRAZENECA  : Egypt receives second shipment of 1.77 million COVID-19 vaccines ..
05/14ASTRAZENECA  : Egypt receives second shipment of 1.77 million COVID-19 vaccines ..
05/14ASTRAZENECA  : Italy audit court rejects public funding for ReiThera COVID-19 va..
05/14ASTRAZENECA  : Italy audit court rejects public funding for ReiThera COVID-19 va..
More news
Financials (USD)
Sales 2021 31 426 M - -
Net income 2021 4 488 M - -
Net Debt 2021 10 883 M - -
P/E ratio 2021 32,7x
Yield 2021 2,57%
Capitalization 145 B 145 B -
EV / Sales 2021 4,98x
EV / Sales 2022 4,36x
Nbr of Employees 76 100
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Average target price 130,45 $
Last Close Price 110,83 $
Spread / Highest target 49,7%
Spread / Average Target 17,7%
Spread / Lowest Target -13,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.16%448 257
ROCHE HOLDING AG-1.80%290 657
PFIZER, INC.8.94%224 020
ABBVIE INC.8.66%205 641
NOVARTIS AG-3.78%200 099